Vertex Pharmaceuticals Inc

2 de jul. de 2026, 20:03 UTC

Vertex Pharmaceuticals shares are higher following FDA approval for expanded use of CASGEVY, now available for children as young as 2 years old.

1 de jul. de 2026, 20:06 UTC

Vertex Pharmaceuticals shares are advancing, reflecting broader market trends. The stock remains above its 20-day moving average despite an earlier session pullback.

30 de jun. de 2026, 20:07 UTC

Vertex Pharmaceuticals is trading lower amid broader market pressures despite promising first-quarter results. Earlier in the session, shares briefly reached a high before declining.

29 de jun. de 2026, 19:31 UTC

Vertex Pharmaceuticals is trading higher, driven by positive analyst sentiment and revised earnings estimates ahead of its upcoming earnings report.

26 de jun. de 2026, 20:04 UTC

Vertex Pharmaceuticals is rising as biotechnology stocks advance during Friday's session. The stock remains above its 20-day moving average after five consecutive higher closes.

25 de jun. de 2026, 20:02 UTC

Vertex Pharmaceuticals is trading higher today amid notable volatility, reflecting a broader trend since Wednesday's close, despite no specific company news.

24 de jun. de 2026, 23:26 UTC

Vertex Pharmaceuticals is lower in after-market hours, driven by declines in the Biotechnology sub-sector. The stock remains above its 20-day moving average.

23 de jun. de 2026, 19:36 UTC

Vertex Pharmaceuticals shares are higher today, recovering from an earlier pullback. The stock remains near the upper end of its one-month trading range.

22 de jun. de 2026, 20:02 UTC

Vertex Pharmaceuticals is higher today, supported by a diverse pipeline in kidney disease and favorable market conditions following easing U.S.-Iran tensions.

18 de jun. de 2026, 19:52 UTC

Vertex Pharmaceuticals shares are lower today as biotechnology stocks face pressure. Earlier in the session, shares peaked before reversing direction.

17 de jun. de 2026, 19:54 UTC

Vertex Pharmaceuticals is rising amid a positive Biotechnology sector trend and favorable Federal Reserve interest rate decisions, boosting investor confidence in healthcare.

16 de jun. de 2026, 23:16 UTC

Vertex Pharmaceuticals Inc shares are lower in after-market hours. Market sentiment is influenced by optimism over a potential U.S.-Iran peace deal.

15 de jun. de 2026, 12:46 UTC

Vertex Pharmaceuticals is roughly flat in pre-market hours, maintaining a routine performance and remaining above its 20-day moving average.

12 de jun. de 2026, 19:36 UTC

Vertex Pharmaceuticals shares are higher today, reflecting stable trading conditions. The stock is positioned above its 20-day moving average, indicating positive market sentiment.

11 de jun. de 2026, 23:56 UTC

Vertex Pharmaceuticals announced clinical benefits of CASGEVY® for severe sickle cell disease. Shares are trading lower in after-market hours, within a typical trading range.

10 de jun. de 2026, 20:03 UTC

Vertex Pharmaceuticals shares are lower as inflation data aligns with forecasts. The stock continues to trade below its 20-day moving average.

9 de jun. de 2026, 19:56 UTC

Vertex Pharmaceuticals shares are higher during Tuesday's session, having peaked earlier, though they have pulled back slightly. No specific news was identified for this movement.

8 de jun. de 2026, 19:36 UTC

Vertex Pharmaceuticals shares are lower despite positive data on ALYFTREK for cystic fibrosis. The decline follows broader market dynamics after a strong U.S. jobs report.

5 de jun. de 2026, 23:06 UTC

Vertex Pharmaceuticals shares are trading lower in after-market hours, with no specific news identified. Broader market conditions may be influencing the stock's movement.

4 de jun. de 2026, 20:02 UTC

RBC reiterated its Outperform rating on Vertex Pharmaceuticals with a $543 price target, contributing to shares advancing despite an earlier pullback.

3 de jun. de 2026, 23:06 UTC

Vertex Pharmaceuticals shares are trading higher in after-market hours. No specific news was identified to explain this movement amid broader market volatility.

2 de jun. de 2026, 20:03 UTC

Vertex Pharmaceuticals' FDA acceptance of povetacicept application fails to lift shares, which are trading lower and below their 20-day moving average.

1 de jun. de 2026, 19:41 UTC

Vertex Pharmaceuticals' Biologics License Application for povetacicept accepted by the FDA. Shares are lower today amid broader market sentiment despite this milestone.

29 de mai. de 2026, 22:06 UTC

Vertex Pharmaceuticals shares are higher in after-market hours, trading near the upper end of their one-month range and above their 20-day moving average.

28 de mai. de 2026, 20:02 UTC

Vertex Pharmaceuticals shares are higher today, continuing a steady upward trend since Wednesday. Broader market reactions to geopolitical tensions are influencing trading.

27 de mai. de 2026, 19:46 UTC

Truist Securities initiated coverage of Vertex Pharmaceuticals with a Buy rating and raised the price target to $542, contributing to today's price gain.

26 de mai. de 2026, 19:56 UTC

Vertex Pharmaceuticals shares are higher today, continuing recent upward momentum. No specific company news was identified to explain the price movement.

22 de mai. de 2026, 19:26 UTC

Vertex Pharmaceuticals shares are higher as Health Canada reviews suzetrigine, a new oral pain treatment. The stock shows modest gains since Thursday's close.

21 de mai. de 2026, 19:56 UTC

Vertex Pharmaceuticals shares rise as Health Canada reviews suzetrigine for acute pain treatment, marking a potential breakthrough in oral pain medication.